Cargando…

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, S Y, Theunissen, J-W, Balibalos, J, Liao-Chan, S, Babcock, M C, Wong, T, Cairns, B, Gonzalez, D, van der Horst, E H, Perez, M, Levashova, Z, Chinn, L, D‘Alessio, J A, Flory, M, Bermudez, A, Jackson, D Y, Ha, E, Monteon, J, Bruhns, M F, Chen, G, Migone, T-S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476018/
https://www.ncbi.nlm.nih.gov/pubmed/26024286
http://dx.doi.org/10.1038/bcj.2015.39
_version_ 1782377535656427520
author Kim, S Y
Theunissen, J-W
Balibalos, J
Liao-Chan, S
Babcock, M C
Wong, T
Cairns, B
Gonzalez, D
van der Horst, E H
Perez, M
Levashova, Z
Chinn, L
D‘Alessio, J A
Flory, M
Bermudez, A
Jackson, D Y
Ha, E
Monteon, J
Bruhns, M F
Chen, G
Migone, T-S
author_facet Kim, S Y
Theunissen, J-W
Balibalos, J
Liao-Chan, S
Babcock, M C
Wong, T
Cairns, B
Gonzalez, D
van der Horst, E H
Perez, M
Levashova, Z
Chinn, L
D‘Alessio, J A
Flory, M
Bermudez, A
Jackson, D Y
Ha, E
Monteon, J
Bruhns, M F
Chen, G
Migone, T-S
author_sort Kim, S Y
collection PubMed
description Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC(50) values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.
format Online
Article
Text
id pubmed-4476018
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44760182015-06-30 A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies Kim, S Y Theunissen, J-W Balibalos, J Liao-Chan, S Babcock, M C Wong, T Cairns, B Gonzalez, D van der Horst, E H Perez, M Levashova, Z Chinn, L D‘Alessio, J A Flory, M Bermudez, A Jackson, D Y Ha, E Monteon, J Bruhns, M F Chen, G Migone, T-S Blood Cancer J Original Article Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC(50) values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs. Nature Publishing Group 2015-05 2015-05-29 /pmc/articles/PMC4476018/ /pubmed/26024286 http://dx.doi.org/10.1038/bcj.2015.39 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Kim, S Y
Theunissen, J-W
Balibalos, J
Liao-Chan, S
Babcock, M C
Wong, T
Cairns, B
Gonzalez, D
van der Horst, E H
Perez, M
Levashova, Z
Chinn, L
D‘Alessio, J A
Flory, M
Bermudez, A
Jackson, D Y
Ha, E
Monteon, J
Bruhns, M F
Chen, G
Migone, T-S
A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title_full A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title_fullStr A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title_full_unstemmed A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title_short A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
title_sort novel antibody–drug conjugate targeting sail for the treatment of hematologic malignancies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476018/
https://www.ncbi.nlm.nih.gov/pubmed/26024286
http://dx.doi.org/10.1038/bcj.2015.39
work_keys_str_mv AT kimsy anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT theunissenjw anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT balibalosj anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT liaochans anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT babcockmc anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT wongt anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT cairnsb anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT gonzalezd anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT vanderhorsteh anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT perezm anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT levashovaz anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT chinnl anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT dalessioja anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT florym anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT bermudeza anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT jacksondy anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT hae anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT monteonj anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT bruhnsmf anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT cheng anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT migonets anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT kimsy novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT theunissenjw novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT balibalosj novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT liaochans novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT babcockmc novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT wongt novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT cairnsb novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT gonzalezd novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT vanderhorsteh novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT perezm novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT levashovaz novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT chinnl novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT dalessioja novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT florym novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT bermudeza novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT jacksondy novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT hae novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT monteonj novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT bruhnsmf novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT cheng novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies
AT migonets novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies